‘Procedes Huc’: Voltaire, Newton, and Locke in Lettres Philosophiques

In Lettres philosophiques, Letter XIII is devoted to Locke, as are Letters XIV–XVII to Newton. The ordering of these letters is not adequately explained by comparing the dates of birth or death of the two thinkers. For the Letter on Locke not only precedes but also ‘frames’ those on Newton, in the sense that it provides the reader with a guide through the philosophical intricacies of Letters XIV–XVII. This works in two ways. On the one hand, in order to defend Newton against his detractors Voltaire broadly adopts Locke’s perspective on the relation among words, ideas and things. On the other hand, he subtly and misleadingly grafts Locke’s epistemology onto the Principia, though it differs from Newton’s epistemology in significant respects. For Locke, unlike Newton, holds that we can identify fixed, permanent limits concerning what kind of thing humanity can know of matter and the universe. Voltaire presents Newton’s ideas as though they respected Locke’s limits. However, we can glimpse Voltaire’s own attitude in the final words of Letter XV: ‘Procedes huc, et non ibis amplius’: Voltaire agrees more closely with Locke than Newton concerning the limits of epistemology

Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy

Background: Vitamin D deficiency has been suggested to favor a poorer outcome of Coronavirus disease-19 (COVID-19). We aimed to assess if 25-hydroxyvitamin-D (25OHD) levels are associated with interleukin 6 (IL-6) levels and with disease severity and mortality in COVID-19. Methods: We prospectively studied 103 in-patients admitted to a Northern-Italian hospital (age 66.1 ± 14.1 years, 70 males) for severely-symptomatic COVID-19. Fifty-two subjects with SARS-CoV-2 infection but mild COVID-19 symptoms (mildly-symptomatic COVID-19 patients) and 206 subjects without SARS-CoV-2 infection were controls. We measured 25OHD and IL-6 levels at admission and focused on respiratory outcome during hospitalization. Results: Severely-symptomatic COVID-19 patients had lower 25OHD levels (18.2 ± 11.4 ng/mL) than mildly-symptomatic COVID-19 patients and non-SARS-CoV-2-infected controls (30.3 ± 8.5 ng/mL and 25.4 ± 9.4 ng/mL, respectively, p < 0.0001 for both comparisons). 25OHD and IL-6 levels were respectively lower and higher in severely-symptomatic COVID-19 patients admitted to intensive care Unit [(ICU), 14.4 ± 8.6 ng/mL and 43.0 (19.0–56.0) pg/mL, respectively], than in those not requiring ICU admission [22.4 ± 1.4 ng/mL, p = 0.0001 and 16.0 (8.0–32.0) pg/mL, p = 0.0002, respectively]. Similar differences were found when comparing COVID-19 patients who died in hospital [13.2 ± 6.4 ng/mL and 45.0 (28.0–99.0) pg/mL] with survivors [19.3 ± 12.0 ng/mL, p = 0.035 and 21.0 (10.5–45.9) pg/mL, p = 0.018, respectively). 25OHD levels inversely correlated with: i) IL-6 levels (ρ − 0.284, p = 0.004); ii) the subsequent need of the ICU admission [relative risk, RR 0.99, 95% confidence interval (95%CI) 0.98–1.00, p = 0.011] regardless of age, gender, presence of at least 1 comorbidity among obesity, diabetes, arterial hypertension, creatinine, IL-6 and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count; iii) mortality (RR 0.97, 95%CI, 0.95–0.99, p = 0.011) regardless of age, gender, presence of diabetes, IL-6 and C-reactive protein and lactate dehydrogenase levels, neutrophil cells, lymphocytes and platelets count. Conclusion: In our COVID-19 patients, low 25OHD levels were inversely correlated with high IL-6 levels and were independent predictors of COVID-19 severity and mortality

Multi-ancestry genome-wide association meta-analysis of Parkinson's disease.

Although over 90 independent risk variants have been identified for Parkinson's disease using genome-wide association studies, most studies have been performed in just one population at a time. Here we performed a large-scale multi-ancestry meta-analysis of Parkinson's disease with 49,049 cases, 18,785 proxy cases and 2,458,063 controls including individuals of European, East Asian, Latin American and African ancestry. In a meta-analysis, we identified 78 independent genome-wide significant loci, including 12 potentially novel loci (MTF2, PIK3CA, ADD1, SYBU, IRS2, USP8, PIGL, FASN, MYLK2, USP25, EP300 and PPP6R2) and fine-mapped 6 putative causal variants at 6 known PD loci. By combining our results with publicly available eQTL data, we identified 25 putative risk genes in these novel loci whose expression is associated with PD risk. This work lays the groundwork for future efforts aimed at identifying PD loci in non-European populations

A fresh look at instrumentation - an introduction

The theme of "instrumentation between science, state and industry" does not square well with the venerable discourse which opposes "science" and "technology" in social studies of science. In this discourse, "technology" stands for the contrary of "science"; it represents the practical uses of science in society at large and is understood as separate from the somehow autonomous sphere of "science" (Layton 1971a). This vocabulary, widespread as it may be, is not very useful for our purposes, and, for that matter, for any inquiry into the role of instruments. Technology, in the sense of technical instruments and the knowledge systems that go with them, pervades all societal systems. There are technologies of science, of industry, of state, and so forth, and it would be ill-advised to assume that, in the end, they all flow out of "science." But even if the crude opposition of science and technology has little analytic value, the dual problem remains: how to effectively conceive the dynamic relationship between scientific spheres and other societal spheres, and how to conceive the role that technological matters play in this relationship

Recital líric

Simon Boccanegra, Brindisi, Luisa Miller i La forza del destio de Verdi ; Das Rheingold i Die Walküre de Wagner ; Cançó d'amor i de guerra de R. Martínez-Valls ; La tempranica de G. Giménez ; L'emigrant de Vives ; Cavalleria rusticana de Mascagni ; Adriana Lecouvreur de Cilea ; La donzella d'Orleans de Txaikovski i Turandot de PucciniOlga Romanko, Maria Uriz, Susan Shafer, Alfred Heilbron, Antoni Lluch, Joan Tomàs i acompanyats al piano per Enrique Ricc

Andrea Chénier

Programa de les funcions d'"Andrea Chénier" d'U. Giordano amb llibret de L. Illica, que van tenir lloc al Gran Teatre del Liceu durant el mes de novembre de 1985. El repartiment va estar format per L. Bartolini com Andrea Chénier, V. Sarindero com a Carlo Gérard, E. Marton com a Maddalena, R. M. Ysàs com la mulata Bersi, C. Fondevila com la comtessa de Coigny, M. Aparici com a Madelon, A. Echeverría com a Roucher, V. Esteve com a Pietro Fleville i Fouquier Tinville, G. Tosi com el "sanculotto" Mathieu, Piero de Palma com un "incredibile", A. Heilbron com l'Abate i J. Castillón com a Schmidt, el majordom i DumasOrquestra del Gran Teatre del Liceu dirigida per Romano Gandolf

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

Background: Genome-wide association studies (GWAS) in Parkinson's disease have increased the scope of biological knowledge about the disease over the past decade. We aimed to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into the causes of Parkinson's disease. / Methods: We did a meta-analysis of 17 datasets from Parkinson's disease GWAS available from European ancestry samples to nominate novel loci for disease risk. These datasets incorporated all available data. We then used these data to estimate heritable risk and develop predictive models of this heritability. We also used large gene expression and methylation resources to examine possible functional consequences as well as tissue, cell type, and biological pathway enrichments for the identified risk factors. Additionally, we examined shared genetic risk between Parkinson's disease and other phenotypes of interest via genetic correlations followed by Mendelian randomisation. / Findings: Between Oct 1, 2017, and Aug 9, 2018, we analysed 7·8 million single nucleotide polymorphisms in 37 688 cases, 18 618 UK Biobank proxy-cases (ie, individuals who do not have Parkinson's disease but have a first degree relative that does), and 1·4 million controls. We identified 90 independent genome-wide significant risk signals across 78 genomic regions, including 38 novel independent risk signals in 37 loci. These 90 variants explained 16–36% of the heritable risk of Parkinson's disease depending on prevalence. Integrating methylation and expression data within a Mendelian randomisation framework identified putatively associated genes at 70 risk signals underlying GWAS loci for follow-up functional studies. Tissue-specific expression enrichment analyses suggested Parkinson's disease loci were heavily brain-enriched, with specific neuronal cell types being implicated from single cell data. We found significant genetic correlations with brain volumes (false discovery rate-adjusted p=0·0035 for intracranial volume, p=0·024 for putamen volume), smoking status (p=0·024), and educational attainment (p=0·038). Mendelian randomisation between cognitive performance and Parkinson's disease risk showed a robust association (p=8·00 × 10−7). / Interpretation: These data provide the most comprehensive survey of genetic risk within Parkinson's disease to date, to the best of our knowledge, by revealing many additional Parkinson's disease risk loci, providing a biological context for these risk factors, and showing that a considerable genetic component of this disease remains unidentified. These associations derived from European ancestry datasets will need to be followed-up with more diverse data. / Funding: The National Institute on Aging at the National Institutes of Health (USA), The Michael J Fox Foundation, and The Parkinson's Foundation (see appendix for full list of funding sources)